alpha particle

(redirected from Alpha emitter)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

alpha particle,

one of the three types of radiation resulting from natural radioactivityradioactivity,
spontaneous disintegration or decay of the nucleus of an atom by emission of particles, usually accompanied by electromagnetic radiation. The energy produced by radioactivity has important military and industrial applications.
..... Click the link for more information.
. Alpha radiation (or alpha rays) was distinguished and named by E. R. Rutherford in 1909, who found by measuring the charge and mass of alpha particles that they are the nuclei of ordinary helium atoms. Alpha particles consist of two protons and two neutrons (see nucleusnucleus,
in physics, the extremely dense central core of an atom. The Nature of the Nucleus
Composition

Atomic nuclei are composed of two types of particles, protons and neutrons, which are collectively known as nucleons.
..... Click the link for more information.
).

alpha particle

(α particle) The nucleus of a helium atom, i.e. a positively charged particle consisting of two protons and two neutrons. It is thus a fully ionized helium atom. Alpha particles are very stable. They are often ejected in nuclear reactions, including alpha decay in which a parent nucleus disintegrates – or breaks up – into an alpha particle and a lighter daughter nucleus.

alpha particle

[′al·fə ‚pärd·ə·kəl]
(atomic physics)
A positively charged particle consisting of two protons and two neutrons, identical with the nucleus of the helium atom; emitted by several radioactive substances.

alpha particle

a helium-4 nucleus, containing two neutrons and two protons, emitted during some radioactive transformations

alpha particle

References in periodicals archive ?
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020.
Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET; whereas, radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters.
On the other hand, the therapeutics market is further segmented into beta emitters, alpha emitters, and brachytherapy isotopes.
Quantitative information about alpha emitters is not conclusive, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies.
Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies.
Alpha emitters are being developed and considered for cancer treatment, however not available commercially.
While, therapeutic market is segmented as Beta emitters, Alpha emitters and brachytherapy.
Therapeutics segments are classified as beta emitters, brachytherapy isotopes, and alpha emitters.
Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.